Quantitative determination of c-erbB-2 in human breast tumours: Potential prognostic significance of low values

European Journal of Cancer

Volumn 34, Issue 4, 1998, Pages 476-481

  Koscielny, S ^a,b   Terrier, Ph ^a   Daver, A ^a   Wafflart, J ^a   Goussard, J ^a   Ricolleau, G ^a   Delvincourt, C ^a   Delarue, J C ^a  

^a FNCLCC   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast tumours; c erbB 2; Prognostic factors

Indexed keywords

ESTROGEN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DNA CONTENT; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR DENSITY;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 0032033686     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10069-7     Document Type: Article

References (41)

1. Weinberg RA. Oncogenes, antioncogenes and the molecular basis of multistep carcinogenesis. Cancer Res 1989, 49, 3713-3721.
2. Van de Vijver M, Van de Bersselaar R, Deville P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked cerbA oncogene. Mol Cell Biol 1987, 7, 2019-2023.
3. Akyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c.erbB.2 gene: a 185 kilodalton glycoprotein with tyrosine kinase activity. Science 1986, 232, 1644-1646.
4. Schechter AL, Stern DF, Vaidyanathan L. The neu oncogene: an erb.B related gene encoding a 185,00-Mr tumour antigen. Nature 1984,312, 513-516.
5. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the protein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1987, 2, 69-72.
6. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989,244,707-712.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2 oncogene. Science 1987, 235, 177-181.
8. Berger MS, Locher GW, Saurer S, et al. Correlation of c-erbB-2 gène amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988, 48, 1238-1243.
9. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2 neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989, 7, 1120-1128.
10. Terrier Ph, Mouriesse H, Loridon B, Gotteland M, May-Levin F, Delarue JC. Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein overexpression in human breast cancer. Acta Oncol 1996, 35, 23-30.
11. Singleton TP, Strickler JG. Clinical and pathologic significance of the c-erbB-2 (HER/neu) oncogene. Pathol Annu 1992, 165-190.
12. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 259 have been followed 15 years. BrJ Cancer 1957, 11, 359-377.
13. Martin PM, Bressot N, Delarue JC, et al. In Gest J, ed. Evaluation des Moyens de Diagnostic du Cancer du Sein. Paris, JMT Conseil, 1981, 173-185.
14. Delarue JC, Mouriesse H, Contesso G, et al. Récepteurs oestrogéniques dans les cancers du sein. Comparaison de 2 méthodes. Ann Biol Clin 1986, 44, 629-633.
15. Blankenstein MA. Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols. Breast Cancer Res Treat 1990, 17, 91-98.
16. Langton BC, Creushaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE. An antigen immunologically related to the external domain of gp!85 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER/neu) oncogene. Cancer Res 1991, 51, 2593-2598.
17. Leitzel K, Teramoto Y, Sampson E, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. JClin Oncol 1992, 10, 1436-1443.
18. SAS/STAT, User's guide, version 6, Fourth Edition Volume 2, Gory, North Carolina, U.S.A., SAS Institute Inc., 1989.
19. Van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. NEnglJMed 1988, 319, 1239-1245.
20. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991, 51, 944-948.
21. Berns EMJJ, Klijn JGM, van Putten WLJ, Van Staveren JL, Portengen H, Foekens JA. c.myc amplification is a better prognostic factor than HER-2/neu amplification in primary breast cancer. Cancer Res 1992, 52, 1107-1113.
22. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in nodenegative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992, 10, 599-605.
23. Neville AM, Bettelheim R, Gelber RD, et al. for the International (Ludwig) Breast Cancer Study Group. Factors predicting treatment responsiveness and prognosis in node negative breast cancer. J Clin Oncol 1992, 10, 696-705.
24. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992, 10, 1049-1056.
25. Levine MN, Andrulis I. The HER-2/neu oncogene in breast cancer: so what is new? J Clin Oncol 1992, 10, 1034-1036.
26. Piffanelli A, Dittadi R, Catozzi L, et al. Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res Treat 1996,37,267-276.
27. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 years follow-up. J Clin Oncol 1992, 10, 1044-1048.
28. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologie grade of malignancy and copy number of c-erbB-2 gene in breast cancer carcinoma. A retrospective analysis of 176 cases. Cancer 1990, 65, 1794-1800.
29. Watanabe T, Fukutomi T, Tsuda H, et al. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay. Jpn J Cancer Res 1993,84, 1279-1286.
30. Adnane J, Gaudray P, Simon MP, Simony TJ, Jeanteur P, Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989, 4, 1389-1395.
31. Zeillinger R, Kury F, Czerwenka K, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989, 4, 109-114.
32. Yamada Y, Yoshimoto M, Murayama Y, et al. Association of elevated expression of the c-erbB-2 protein with spread of breast cancer. Jpn J Cancer Res 1989, 80, 1192-1198.
33. Uehara T, Kaneko Y, Kanda N, et al. c-erbB-2 and c-erbA-1 (ear-1) gene amplification and c-erbB-2 protein expression in Japanese breast cancers: their relationship to the histology and other disease parameters. Jpn J Cancer Res 1990, 81, 620-624.
34. Berns EM, Klijn JG, Van Staveren JL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of the amplification of the oncogenes c.myc, HER-2/neu and int.2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992,28,697-700.
35. Thorpe SM, Christensen JBJ, Rasmussen BB, Rose C. Short recurrence-free survival associated with high estrogen receptor levels in the natural history of postmenopausal primary breast cancer. Eur J Cancer 1993, 29A, 971-977.
36. Sancho-Garnier H, Delarue JC, Mouriesse H, et al. Is the negative prognostic value of high estrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product? Eur J Cancer 1995, 31A, 1851-1855.
37. Robertson KW, Reeves JR, Smith G, et al. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 1996, 56, 3823-3830.
38. Russell KG, Hung MC. Translational repression of the neu proto-oncogene by estrogen stimulated estrogen receptor. Cancer Res 1992,52,6624-6629.
39. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM. Treatment decisions in axillary node-negative breast cancer patients. J Natl Cancer Inst Monogr 1992, 11, 173180.
40. Tsuda H, Hirohoshi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst. l/int.2 and c.erbB.2/ear.l. Cancer Res 1989, 49, 3104-3108.
41. Mittra I, Mac Rae KD. A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer 1991,27, 1574-1583.